1-4 of 4
Richard Schwartz
Close
Sort by
Journal Articles

Initial Results of PX-171-003, An Open-Label, Single-Arm, Phase II Studyof Carfilzomib (CFZ) in Patients with Relapsed and Refractory Multiple Myeloma (MM)

Sundar Jagannath, MD, Ravi Vij, MD, A. Keith Stewart, MBChB, George Somlo, MD, Andrzej Jakubowiak, MD, PhD, Tony Reiman, MD, Suzanne Trudel, MD, Jessica Taylor, BA, Diana Fuhrman, BSN, Scott Cruickshank, MS, Richard Schwartz, MD, Lori Kunkel, MD, David Siegel, MD, PhD, The Multiple Myeloma Research Consortium (MMRC)
Journal: Blood
Blood (2008) 112 (11): 864.
https://doi.org/10.1182/blood.V112.11.864.864
Published: 2008
Journal Articles

Initial Results of PX-171-004, An Open-Label, Single-Arm, Phase II Study of Carfilzomib (CFZ) in Patients with Relapsed Myeloma (MM)

Ravi Vij, MD, Michael Wang, MD, Robert Orlowski, MD, PhD, A. Keith Stewart, MBChB, Sundar Jagannath, MD, Vishal Kukreti, MD, FRCPC, Jessica Taylor, BA, Diana Fuhrman, BSN, Scott Cruickshank, MS, Richard Schwartz, MD, Lori Kunkel, MD, David Siegel, MD, PhD, The Multiple Myeloma Research Consortium (MMRC)
Journal: Blood
Blood (2008) 112 (11): 865.
https://doi.org/10.1182/blood.V112.11.865.865
Published: 2008
Journal Articles

Safety and Efficacy Study of Subcutaneous Homoharringtonine (SC HHT) in Imatinib (IM)-Resistant Chronic Myeloid Leukemia (CML) with the T315I Mutation - Initial Report of a Phase II Trial.

H. Jean Khoury, MD, Mauricette Michallet, MD, Selim Corm, MD, Lydia Roy, MD, Dan Jones, MD, PhD, Andreas Hochhaus, MD, Hagop Kantarjian, MD, Annie-Claude Benichou, MD, Richard Schwartz, MD, Jorge Cortes, MD
Journal: Blood
Blood (2007) 110 (11): 1050.
https://doi.org/10.1182/blood.V110.11.1050.1050
Published: 2007
Journal Articles

Distinctions Between Idiopathic Ineffective Erythropoiesis and di Guglielmo’s Disease: Clinical and Biochemical Differences

Philip M. Eastman, M.D., Richard Schwartz, Stanley L. Schrier, M.D.
Journal: Blood
Blood (1972) 40 (4): 487–499.
https://doi.org/10.1182/blood.V40.4.487.487
Published: 1972